Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
As a result of COVID-19 and measures taken by the Canadian Government to reduce the transmission of the virus, in-person psychology services have been suspended. Psychology services are now being conducted via video conferencing. The purpose of the current project is to pilot-test a 6-week Self Compassion Treatment for Chronic Pain delivered virtually, in order to understand its utility in the current environment. The treatment is to be delivered through a secure professional ZOOM licence. Objective 1 of the project is to assess the feasibility and acceptability of attending the treatment group through virtual participation. Objective 2 is to assess the effectiveness of the group treatment in improving self-compassion, mental health, relationship with pain, and quality of life.
Description: Change over time in scores on the Self-Compassion Scale (SCS) (score range is 12-60 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Self-Compassion Scale (SCS) Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Pain Disability Index (score range is 0-70 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Pain Disability Index Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the on the Chronic Pain Acceptance Questionnaire - 8 (CPAQ-8) (score range is 0-48 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Chronic Pain Acceptance Questionnaire - 8 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the on the Pain Catastrophizing Scale-6 (PCS-6) (score range is 0-24 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Pain Catastrophizing Scale -6 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 (PSEQ-4) (score range is 0-24 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Scores on the Pain Self-Efficacy Questionnaire-4 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Numeric Rating Scale (NRS) for pain (score range is 0-10 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Pain Intensity Time: at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Patient Health Questionnaire-9 (PHQ-9) (score range is 0-27 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Depression Symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9) Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Generalized Anxiety Scale (GAD-7) (score range is 0-21 with decreases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Changes over time in Anxiety Symptoms as measured by the Generalized Anxiety Scale-7 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Change over time in scores on the Physical Health and Mental Health Quality of Life scores from the PROMIS GLOBAL-10 (score range is 7-35 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Change over time in Quality of Life as measured by the PROMIS GLOBAL- 10 Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Changes over time in score on the Mindfulness Attention and Awareness Scale (MAAS) (score range is 15-90 with increases in scores meaning better outcome). Change over time to be assessed via repeated measures Analysis of Variance (ANOVA)
Measure: Changes over time in Mindfulness Time: baseline, at treatment end (6-weeks after beginning treatment) and 3 months laterDescription: Scores on the Client Satisfaction Questionnaire
Measure: Client Satisfaction Time: post treatment (6 weeks after beginning the treatment)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports